Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
19 evidence topics · 15 sources
Mechanism: AAV5 vector carrying a microRNA that non-selectively lowers human huntingtin
Non-selective huntingtin knockdown: company description of the construct
miQURE platform: degradation of disease-causing transcripts and secondary exosome-mediated silencing
Mechanistic goals of the phase I/II studies: biodistribution and durable knockdown of huntingtin and exon 1 huntingtin
Axonal transport of the vector to other brain regions affected by the disease
Construct attributes stated by the sponsor: suppression of huntingtin and of the exon 1 isoform
Construct design: targeting of huntingtin exon 1 and total silencing of both alleles
“In the first approach, total silencing of wild-type and mtHTT was achieved by targeting exon 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-one miHTT variants were designed to target HTT exon 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the first time, we show that the therapeutic pri-miRNA scaffold influences HTT knock-down and guide strand processing in vivo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Scaffold selection and absence of passenger strand activity in vitro
Suppression of mutant huntingtin aggregates and neuronal dysfunction in a lentiviral rat model
“Our data demonstrated suppression of mutant HTT messenger RNA, which almost completely prevented mutant HTT aggregate formation, and ultimately resulted in suppression of DARPP-32-associated neuronal dysfunction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ultimately, AAV5-delivered-miRNA-mediated HTT lowering did not cause activation of microglia or astrocytes suggesting no immune response to the AAV5 vector or therapeutic precursor sequences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continuous microRNA expression after a single vector administration
“Importantly, the AAV-delivered-miRNA-based gene therapy approach comprises continual expression of artificial miRNAs following a single administration of an AAV vector, resulting in long-term HTT lowering.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for lowering huntingtin messenger RNA rather than the protein
“miRNA-based lowering strategies are designed to lower HTT mRNA levels and thereby reduce the overall mutant HTT protein.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The latter is crucial for assessment of tolerability of non-selective HTT lowering, in which case the remaining levels of endogenous HTT are relevant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cell types transduced by AAV5 after intracranial injection
Off-target assessment in patient-derived neurons and astrocytes
“Small RNA sequencing showed that mature miHTT was processed correctly without off-target passenger strand.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No cellular microRNAs were dysregulated, indicating that endogenous RNAi machinery was unaffected by miHTT overexpression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“qPCR validation of in silico-predicted off-target transcripts, next-generation sequencing, and pathway analysis confirmed absence of dysregulated genes due to sequence homology or seed-sequence activity of miHTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-allele-selective lowering: tolerability of wild-type huntingtin reduction in humanized mice
“Importantly, non-selective suppression of huntingtin was generally tolerated, however high dose AAV5-miHTT did induce astrogliosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, we also observed that potent reduction of wild type HTT (wtHTT) in Hu21 control mice was tolerated up to 7 months post-injection but may induce impairment of motor coordination and striatal atrophy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Taken together, our data suggests that in the context of HD, the therapeutic benefits of mHTT reduction may outweigh the potentially detrimental effects of wtHTT loss following non-selective HTT lowering.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-allele-selective lowering: unknown consequences in adults stated to trial participants
Extracellular vesicle-mediated spread of the therapeutic microRNA between cells
“Preclinical studies demonstrate the brain-wide spread of AAV5-miHTT following a single intrastriatal injection, which is partly mediated by neuronal transport.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Transfer of miHTT to recipient (HEK-293T, HeLa, and HD patient-derived neurons) cells was observed, which significantly reduced HTT mRNA levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In summary, we provide evidence that an engineered miRNA” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“is loaded into EVs, transported across extracellular space, and taken up by neighboring cells, and importantly, that miHTT is active in recipient cells downregulating HTT expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Two routes of spread from the injection site: axonal transport and vesicle transport
“(ii) The AAV is then transported to distant brain regions (e.g., the cortex) via axonal anterograde/retrograde transport.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“(iii) Because of its miR-451 scaffold, miHTT is actively and preferentially loaded into EVs, resulting in intercellular transport of miHTT, independently of neuronal connections, to adjacent cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exon 1 huntingtin protein as a target: N-terminal fragments and aberrant splicing
“Various mechanisms lead to the production of N-terminal Huntingtin protein fragments, which are reportedly more toxic than the full-length protein.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistently accumulating evidence indicates that small N-terminal fragments containing extended polyQ tracts significantly contribute mHTT cellular mislocalization, aggregation and toxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AMT-130 is an AAV5-delivered miRNA which is administered through a one-time intrastriatal injection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Target sequence present in both full-length and exon 1 huntingtin transcripts
“We have developed an engineered microRNA targeting the HTT exon 1 sequence (miHTT), delivered via adeno-associated virus serotype 5 (AAV5). The target sequence of miHTT is present in both FL HTT and HTT1a transcripts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote